CA2300362A1 - Coat-protein-modified baculovirus vector for gene therapy - Google Patents

Coat-protein-modified baculovirus vector for gene therapy Download PDF

Info

Publication number
CA2300362A1
CA2300362A1 CA002300362A CA2300362A CA2300362A1 CA 2300362 A1 CA2300362 A1 CA 2300362A1 CA 002300362 A CA002300362 A CA 002300362A CA 2300362 A CA2300362 A CA 2300362A CA 2300362 A1 CA2300362 A1 CA 2300362A1
Authority
CA
Canada
Prior art keywords
vector
sequence
vector according
dna sequence
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300362A
Other languages
English (en)
French (fr)
Inventor
Christian Hofmann
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HepaVec AG fur Gentherapie
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300362A1 publication Critical patent/CA2300362A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002300362A 1997-08-15 1998-08-05 Coat-protein-modified baculovirus vector for gene therapy Abandoned CA2300362A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997135593 DE19735593C2 (de) 1997-08-15 1997-08-15 Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
DE19735593.5 1997-08-15
PCT/DE1998/002255 WO1999009193A1 (de) 1997-08-15 1998-08-05 Hüllprotein-modifizierter baculovirus-vektor für die gentherapie

Publications (1)

Publication Number Publication Date
CA2300362A1 true CA2300362A1 (en) 1999-02-25

Family

ID=7839201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300362A Abandoned CA2300362A1 (en) 1997-08-15 1998-08-05 Coat-protein-modified baculovirus vector for gene therapy

Country Status (6)

Country Link
EP (1) EP1003896A1 (es)
JP (1) JP2003530064A (es)
CA (1) CA2300362A1 (es)
DE (1) DE19735593C2 (es)
ES (1) ES2150894T1 (es)
WO (1) WO1999009193A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6607912B2 (en) 2000-08-11 2003-08-19 Boyce Thompson Institute For Plant Research, Inc. GP64-null baculoviruses pseudotyped with heterologous envelope proteins
WO2002072853A1 (en) * 2001-03-12 2002-09-19 Ark Therapeutics Limited Avidin-pseudotyped viral vectors and their use
EP1392837A2 (en) * 2001-05-29 2004-03-03 Ark Therapeutics Limited Gene delivery via a baculovirus vector
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
AU2003266628A1 (en) * 2002-09-25 2004-04-19 Osaka Industrial Promotion Organization Baculovirus vector, method of constructing baculovirus vector and gene transfer method
MXPA06008507A (es) 2004-02-02 2008-02-13 Ambrx Inc Cuatro polipeptidos en haz helicoidal humanos modificados y sus usos.
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
GB0425739D0 (en) * 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
CA3005835C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2007007581A (es) 2004-12-22 2007-07-24 Ambrx Inc Composiciones de amino acil-arnt sintetasa y sus usos.
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
PT2061878E (pt) 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
BRPI0810622A2 (pt) 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
CN101918026B (zh) 2007-11-20 2016-03-02 Ambrx公司 经修饰胰岛素多肽和其用途
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
MX343802B (es) 2008-09-26 2016-11-23 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
JP5694171B2 (ja) 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JPWO2016059911A1 (ja) * 2014-10-17 2017-07-27 国立大学法人金沢大学 マラリアワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
CN1172435A (zh) * 1994-09-23 1998-02-04 综合医院公司 使用非哺乳动物dna病毒在哺乳动物细胞中表达外源基因
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP1003896A1 (de) 2000-05-31
DE19735593A1 (de) 1999-02-18
WO1999009193A1 (de) 1999-02-25
JP2003530064A (ja) 2003-10-14
ES2150894T1 (es) 2000-12-16
DE19735593C2 (de) 1999-08-26

Similar Documents

Publication Publication Date Title
CA2300362A1 (en) Coat-protein-modified baculovirus vector for gene therapy
CA2148934C (en) Targetable vector particles
JP3681752B2 (ja) 遺伝子治療に使用できる宿主 − ベクタ系
US20050181507A1 (en) Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP0851769B1 (en) Gene therapy using ovine adenoviral vectors
WO2001058940A2 (en) Adenoviral capsid containing chimeric protein ix
IL214413A (en) Human Recombinant Human Adenovirus Type 35, Nucleic Acid Encoded, Nucleic Acid Cell and Method
JP2001522236A (ja) 改変アデノウイルスファイバーおよび標的アデノウイルス
US6872528B2 (en) Highly productive packaging lines
AU2002315947A1 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
AU717202B2 (en) New variants of apolipoprotein A-I
US7410954B2 (en) Adenovirus serotype 30 (Ad30)
US5736360A (en) Endothelial cell tropic compositions and methods of making and using the same
AU729934B2 (en) Retroviral vector and its use in gene therapy
WO1998047916A1 (en) Bifunctional polypeptides for cell-specific viral targeting
JP2000157289A (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクタ―
AU747763B2 (en) Method for helper virus-free packaging of a gene vector DNA
CA2131415C (en) Vector for liver-specific gene therapy
US20020137213A1 (en) Adenovirus particles with mutagenized fiber proteins
EP1279738A1 (en) Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1195440A1 (en) Gene delivery vectors for stem cells
CA2047363C (en) Recombinant therapies for infection and hyperproliferative disorders
EP0870050A2 (en) Toxic-protein expressing viruses and producer cell lines
Michael Development of tropism-modified adenoviral vectors for targeted gene delivery
Lea et al. The Scope of Viral Vectors for the Transduction of Haemopoietic Cells

Legal Events

Date Code Title Description
FZDE Discontinued